Anna de Mauro, Rosa Cortese, Giulia Fadda, Nicola De Stefano, Ludwig Kappos, Maria Pia Sormani, Brenda Banwell, Cristina Granziera, Alessandro Cagol
PRLs are frequent in POMS. Limited comparative data suggest that PRLs may have high diagnostic specificity, whereas CVS appears more variable; however, pediatric diagnostic accuracy evidence remains scarce. Further pediatric-specific studies are needed to define the optimal diagnostic use of these biomarkers in POMS.
BACKGROUND: Susceptibility-based MRI biomarkers, including paramagnetic rim lesions (PRLs) and central vein sign (CVS), were incorporated into the 2024 McDonald criteria because they improve diagnostic specificity in adult-onset MS; however, their role in pediatric-onset MS (POMS) remains incompletely defined.
OBJECTIVE: To synthesize current evidence on the prevalence and diagnostic value of PRLs and CVS in POMS.
METHODS: We conducted a PRISMA-compliant systematic review and random-effects meta-analysis of studies reporting PRLs and/or CVS in POMS. Outcomes included the proportion of patients with ≥1 PRL, the mean proportion of CVS-positive lesions, and fulfillment of CVS-based thresholds.
RESULTS: Eleven studies were included. Across seven studies, the pooled proportion of POMS patients with ≥1 PRL was 71.6% (95% CI 61.1-80.2; n=149), with low between-study heterogeneity. Across six studies, the pooled mean proportion of CVS-positive lesions was 57.9% (95% CI 39.7-76.2; n=99), and 66.2% (95% CI 10.5-97.0; n=219) of patients fulfilled the 40%-CVS rule, with substantial variability across studies. In comparative analyses, PRLs showed high specificity for POMS, while CVS was more prevalent than in mimics; however, limited data precluded quantitative evaluation.
CONCLUSION: PRLs are frequent in POMS. Limited comparative data suggest that PRLs may have high diagnostic specificity, whereas CVS appears more variable; however, pediatric diagnostic accuracy evidence remains scarce. Further pediatric-specific studies are needed to define the optimal diagnostic use of these biomarkers in POMS.